炎症标志物对实体瘤预后价值的研究进展

Advances in the evaluation of inflammatory response markers in the prognosis of solid tumors

全身炎症反应与肿瘤的发生发展密切相关。越来越多的研究证实炎症反应在肿瘤的预后中发挥着重要作用。炎症反应在外周血中主要反映为炎症蛋白与炎症细胞计数的变化。近年来,基于炎症蛋白和炎症细胞计数的全身炎症反应标志物如格拉斯哥预后评分,中性粒细胞与淋巴细胞比,淋巴细胞与单核细胞比,血小板与淋巴细胞比等,已被证实与多种恶性肿瘤的预后相关。本文旨在对基于炎症蛋白和炎症细胞计数的全身炎症标志物在实体瘤的预后价值中的突出潜力和局限性做一综述。

Systemic inflammatory response is closely associated with the occurrence and development of tumors.More and more studies have confirmed that inflammation plays an important role in the prognosis of tumors.The inflammatory response in the blood system is characterized by changes in the content of inflammatory proteins and inflammatory cells.In recent years,systemic inflammatory markers based on inflammatory protein and inflammatory cell counts such as Glasgow prognosis score,neutrophil to lymphocyte ratio,lymphocyte to monocyte ratio,platelet to lymphocyte ratio,etc,have been confirmed to be associated with the prognosis of various tumor patients.This article reviews the latest research progress on the highlighting potential and limitations of inflammatory markers based on inflammatory protein and inflammatory cell count in the evaluation of the prognosis of the patients with solid tumors.